Scheme 1.
pH-responsive PEGylation strategy for the delivery of mPEG-CDM-modified sEVs, where the PEG coating stabilizes the vesicles under physiological conditions (pH ∼7.4), prolonging their circulation time, and is cleaved in acidic environments to promote their passive accumulation at disease sites in both glioma and ischemic stroke.
